20-Mar-2026
Stifel Nicolaus Sticks to Their Buy Rating for DarioHealth (DRIO)
TipRanks (Fri, 20-Mar 7:39 AM ET)
TD Cowen Reaffirms Their Hold Rating on DarioHealth (DRIO)
TipRanks (Fri, 20-Mar 6:37 AM ET)
Product Liability Risks Pose Financial and Operational Threats to DarioHealth
TipRanks (Fri, 20-Mar 2:00 AM ET)
DarioHealth Earnings Call: Growth Promise, Execution Test
TipRanks (Thu, 19-Mar 8:06 PM ET)
DarioHealth reports Q4 results
Seeking Alpha News (Thu, 19-Mar 6:33 AM ET)
DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
PRNewswire (Thu, 19-Mar 6:30 AM ET)
DarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026
PRNewswire (Wed, 11-Mar 8:30 AM ET)
PRNewswire (Tue, 10-Mar 8:00 AM ET)
PRNewswire (Tue, 3-Mar 8:00 AM ET)
PRNewswire (Wed, 21-Jan 8:00 AM ET)
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Dariohealth Corp. trades on the NASDAQ stock market under the symbol DRIO.
As of March 20, 2026, DRIO stock price declined to $7.99 with 26,819 million shares trading.
DRIO has a beta of 0.54, meaning it tends to be less sensitive to market movements. DRIO has a correlation of 0.01 to the broad based SPY ETF.
DRIO has a market cap of $54.00 million. This is considered a Micro Cap stock.
Last quarter Dariohealth Corp. reported $5 million in Revenue and -$.82 earnings per share. This beat revenue expectation by $123,050 and exceeded earnings estimates by $.85.
In the last 3 years, DRIO traded as high as $91.60 and as low as $5.94.
The top ETF exchange traded funds that DRIO belongs to (by Net Assets): VXF, DFAS.
DRIO has underperformed the market in the last year with a price return of -43.4% while the SPY ETF gained +16.6%. DRIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -30.8% and -17.6%, respectively, while the SPY returned -4.4% and -3.3%, respectively.
DRIO support price is $7.48 and resistance is $9.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DRIO shares will trade within this expected range on the day.